Cited by

• Approvals and Timing of New Formulations of Novel Drugs Approved by the US Food and Drug Administration Between 1995 and 2010 and Followed Through 2021.

  Gupta R, Morten CJ, Zhu AY, Ramachandran R, Shah ND, Ross JS. Gupta R, et al. JAMA Health Forum. 2022 May 20;3(5):e221096. doi: 10.1001/jamahealthforum.2022.1096. eCollection 2022 May. JAMA Health Forum. 2022. PMID: 35977259 Free PMC article.
• Exploring the feasibility of using real-world data from a large clinical data research network to simulate clinical trials of Alzheimer's disease.

  Chen Z, Zhang H, Guo Y, George TJ, Prosperi M, Hogan WR, He Z, Shenkman EA, Wang F, Bian J. Chen Z, et al. NPJ Digit Med. 2021 May 14;4(1):84. doi: 10.1038/s41746-021-00452-1. NPJ Digit Med. 2021. PMID: 33990663 Free PMC article.
• Sex Differences in the Prevalent Use of Oral Formulations of Cholinesterase Inhibitors in Older Adults with Dementia.

  Zhu L, Rochon PA, Gruneir A, Wu W, Giannakeas V, Austin PC, Stall NM, McCarthy L, Alberga A, Herrmann N, Gill SS, Bronskill SE. Zhu L, et al. Drugs Aging. 2019 Sep;36(9):875-884. doi: 10.1007/s40266-019-00690-9. Drugs Aging. 2019. PMID: 31309528
• Bright Side of Lignin Depolymerization: Toward New Platform Chemicals.

  Sun Z, Fridrich B, de Santi A, Elangovan S, Barta K. Sun Z, et al. Chem Rev. 2018 Jan 24;118(2):614-678. doi: 10.1021/acs.chemrev.7b00588. Epub 2018 Jan 16. Chem Rev. 2018. PMID: 29337543 Free PMC article.
• The Use of Cholinesterase Inhibitors Across All Stages of Alzheimer's Disease.

  Deardorff WJ, Feen E, Grossberg GT. Deardorff WJ, et al. Drugs Aging. 2015 Jul;32(7):537-47. doi: 10.1007/s40266-015-0273-x. Drugs Aging. 2015. PMID: 26033268 Review.